954 related articles for article (PubMed ID: 19248090)
1. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies.
Carrier N; Cossette P; Daniel C; de Brum-Fernandes A; Liang P; Ménard HA; Boire G
Arthritis Rheum; 2009 Mar; 60(3):698-707. PubMed ID: 19248090
[TBL] [Abstract][Full Text] [Related]
2. The HLA-DRB1 shared epitope is not associated with antibodies against cyclic citrullinated peptide in Chinese patients with rheumatoid arthritis.
Xue Y; Zhang J; Chen YM; Guan M; Zheng SG; Zou HJ
Scand J Rheumatol; 2008; 37(3):183-7. PubMed ID: 18465452
[TBL] [Abstract][Full Text] [Related]
3. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles.
Irigoyen P; Lee AT; Wener MH; Li W; Kern M; Batliwalla F; Lum RF; Massarotti E; Weisman M; Bombardier C; Remmers EF; Kastner DL; Seldin MF; Criswell LA; Gregersen PK
Arthritis Rheum; 2005 Dec; 52(12):3813-8. PubMed ID: 16320316
[TBL] [Abstract][Full Text] [Related]
4. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility.
van der Helm-van Mil AH; Huizinga TW; Schreuder GM; Breedveld FC; de Vries RR; Toes RE
Arthritis Rheum; 2005 Sep; 52(9):2637-44. PubMed ID: 16142711
[TBL] [Abstract][Full Text] [Related]
5. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
van der Helm-van Mil AH; Verpoort KN; Breedveld FC; Huizinga TW; Toes RE; de Vries RR
Arthritis Rheum; 2006 Apr; 54(4):1117-21. PubMed ID: 16572446
[TBL] [Abstract][Full Text] [Related]
6. Expression of QK/QR/RRRAA or DERAA motifs at the third hypervariable region of HLA-DRB1 and disease severity in rheumatoid arthritis.
Khani-Hanjani A; Lacaille D; Horne C; Chalmers A; Hoar DI; Balshaw R; Keown PA
J Rheumatol; 2002 Jul; 29(7):1358-65. PubMed ID: 12136889
[TBL] [Abstract][Full Text] [Related]
7. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis.
Boire G; Cossette P; de Brum-Fernandes AJ; Liang P; Niyonsenga T; Zhou ZJ; Carrier N; Daniel C; Ménard HA
Arthritis Res Ther; 2005; 7(3):R592-603. PubMed ID: 15899046
[TBL] [Abstract][Full Text] [Related]
8. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations.
van der Woude D; Lie BA; Lundström E; Balsa A; Feitsma AL; Houwing-Duistermaat JJ; Verduijn W; Nordang GB; Alfredsson L; Klareskog L; Pascual-Salcedo D; Gonzalez-Gay MA; Lopez-Nevot MA; Valero F; Roep BO; Huizinga TW; Kvien TK; Martín J; Padyukov L; de Vries RR; Toes RE
Arthritis Rheum; 2010 May; 62(5):1236-45. PubMed ID: 20131291
[TBL] [Abstract][Full Text] [Related]
9. Redefining the HLA and RA association: to be or not to be anti-CCP positive.
de Vries RR; Huizinga TW; Toes RE
J Autoimmun; 2005; 25 Suppl():21-5. PubMed ID: 16257178
[TBL] [Abstract][Full Text] [Related]
10. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis.
Goëb V; Dieudé P; Daveau R; Thomas-L'otellier M; Jouen F; Hau F; Boumier P; Tron F; Gilbert D; Fardellone P; Cornélis F; Le Loët X; Vittecoq O
Rheumatology (Oxford); 2008 Aug; 47(8):1208-12. PubMed ID: 18535030
[TBL] [Abstract][Full Text] [Related]
11. Smoking increases rheumatoid arthritis susceptibility in individuals carrying the HLA-DRB1 shared epitope, regardless of rheumatoid factor or anti-cyclic citrullinated peptide antibody status.
Bang SY; Lee KH; Cho SK; Lee HS; Lee KW; Bae SC
Arthritis Rheum; 2010 Feb; 62(2):369-77. PubMed ID: 20112396
[TBL] [Abstract][Full Text] [Related]
12. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins.
Huizinga TW; Amos CI; van der Helm-van Mil AH; Chen W; van Gaalen FA; Jawaheer D; Schreuder GM; Wener M; Breedveld FC; Ahmad N; Lum RF; de Vries RR; Gregersen PK; Toes RE; Criswell LA
Arthritis Rheum; 2005 Nov; 52(11):3433-8. PubMed ID: 16255021
[TBL] [Abstract][Full Text] [Related]
13. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide.
van der Helm-van Mil AH; Verpoort KN; le Cessie S; Huizinga TW; de Vries RR; Toes RE
Arthritis Rheum; 2007 Feb; 56(2):425-32. PubMed ID: 17265477
[TBL] [Abstract][Full Text] [Related]
14. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
15. Association of anti-cyclic citrullinated peptide antibody levels with PADI4 haplotypes in early rheumatoid arthritis and with shared epitope alleles in very late rheumatoid arthritis.
Cha S; Choi CB; Han TU; Kang CP; Kang C; Bae SC
Arthritis Rheum; 2007 May; 56(5):1454-63. PubMed ID: 17469103
[TBL] [Abstract][Full Text] [Related]
16. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
17. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen.
Auger I; Sebbag M; Vincent C; Balandraud N; Guis S; Nogueira L; Svensson B; Cantagrel A; Serre G; Roudier J
Arthritis Rheum; 2005 Nov; 52(11):3424-32. PubMed ID: 16255019
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
[TBL] [Abstract][Full Text] [Related]
19. The PTPN22 1858C/T polymorphism is associated with anti-cyclic citrullinated peptide antibody-positive early rheumatoid arthritis in northern Sweden.
Kokkonen H; Johansson M; Innala L; Jidell E; Rantapää-Dahlqvist S
Arthritis Res Ther; 2007; 9(3):R56. PubMed ID: 17553139
[TBL] [Abstract][Full Text] [Related]
20. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles.
Verpoort KN; Cheung K; Ioan-Facsinay A; van der Helm-van Mil AH; de Vries-Bouwstra JK; Allaart CF; Drijfhout JW; de Vries RR; Breedveld FC; Huizinga TW; Pruijn GJ; Toes RE
Arthritis Rheum; 2007 Dec; 56(12):3949-52. PubMed ID: 18050209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
